[1] Fallon M: Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome.Journal of clinical gastroenterology 2005, 0005:138-142.

[2] Fallon MB: Hepatopulmonary syndrome: more than just a matter of tone? Hepatology 2006, 43:912-4.

[3] Ho V: Current concepts in the management of hepatopulmonary syndrome. Vascular health and risk management 2008, 4:1035-1041.

[4] Krowka MJ, Fallon MB: Liver transplantation for hepatopulmonary syndrome (HPS): what is the MESSAGE? American journal of transplantation: offcial journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008, 8:911-912.

[5] Deberaldini M, Arcanjo AB, Melo E, da Silva RF, Felicio HC, Arroyo PC, Jr., Duca WJ, Cordeiro JA, da Silva RC: Hepatopulmonary syndrome: morbidity and survival after liver transplantation. Transplantation proceedings 2008, 40:3512-3516.

[6] Lima B, Martinelli A, Franca AV: [Hepatopulmonary syndrome: pathogenesis, diagnosis and treatment].Arquivos de gastroenterologia 2004, 41:250-258.

[7] Zhang ZJ, Yang CQ: Progress in investigating the pathogenesis of hepatopulmonary syndrome. Hepatobiliary Pancreat Dis Int 2010, 9:355-360.

[8] Zhang J, Fallon MB: Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nature reviews Gastroenterology & hepatology 2012, 9:539-549.

[9] Rodriguez-Roisin R, Barbera JA: Hepatopulmonary syndrome: is NO the right answer? Gastroenterology 1997, 113:682-684.

[10] Vettukattil JJ, Stumper O: Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome:correlation with pulmonary dysfunction. Journal of hepatology 1999, 31:192-193.

[11] Carter EP, Hartsfield CL, Miyazono M, Jakkula M, Morris KG, Jr., McMurtry IF: Regulation of heme oxygenase-1 by nitric oxide during hepatopulmonary syndrome. American journal of physiology Lung cellular and molecular physiology 2002, 283:L346-353.

[12] Aller R, Moya J, Avila S, Villa J: Implications of estradiol and progesterone in pulmonary vasodilatation in cirrhotic patients. Journal of Endocrinology Investigation 2002, 25:4-10.

[13] Cremona G, Higenbottam TW, Mayoral V, Alexander G, Demoncheaux E, Borland C, Roe P, Jones GJ:Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. The European respiratory journal 1995, 8:1883-1885.

[14] Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, Zerbib E, Dulmet E, Moreau R, Dinh-Xuan AT, Simonneau G, Herve P: Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats.American journal of respiratory and critical care medicine 2001, 164:879-885.

[15] Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD: The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997, 113:606-614.

[16] Zhang M, Luo B, Chen SJ, Abrams GA, Fallon MB: Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. The American journal of physiology 1999,277:G944-G952.

[17] Rolla G: Hepatopulmonary syndrome: role of nitric oxide and clinical aspects. Digestive and liver disease:offcial journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2004, 36:303-308.

[18] Gomez FP, Barbera JA, Roca J, Burgos F, Gistau C, Rodriguez-Roisin R: Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology 2006, 43:1084-1091.

[19] Brussino L, Bucca C, Morello M, Scappaticci E, Mauro M, Rolla G: Effect on dyspnoea and hypoxaemia of inhaled N(G)-nitro-L-arginine methyl ester in hepatopulmonary syndrome. Lancet 2003, 362:43-44.

[20] Schleicher M, Yu J, Murata T, Derakhshan B, Atochin D, Qian L, Kashiwagi S, Di Lorenzo A, Harrison KD,Huang PL, Sessa WC: The Akt1-eNOS axis illustrates the specifcity of kinase-substrate relationships in vivo. Sci Signal 2009, 2:41.

[21] Godecke A, Schrader J: Adaptive mechanisms of the cardiovascular system in transgenic mice--lessons from eNOS and myoglobin knockout mice. Basic Res Cardiol 2000, 95:492-498.

[22] Lorenz M, Klinkner L, Baumann G, Stangl K, Stangl V: Endothelial NO Production is Mandatory for Epigallocatechin-3-gallate (EGCG)-induced Vasodilation: Results from eNOS Knockout (eNOS-/-) Mice. J Cardiovasc Pharmacol 2015.

[23] Kuhlencordt PJ, Rosel E, Gerszten RE, Morales-Ruiz M, Dombkowski D, Atkinson WJ, Han F, Preffer F,Rosenzweig A, Sessa WC, Gimbrone MA, Jr., Ertl G, Huang PL: Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells. Am J Physiol Cell Physiol 2004,286:C1195-C1202.

[24] Luo B, Abrams GA, Fallon MB: Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction. Journal of hepatology 1998, 29:571-578.

[25] Luo B, Liu L, Tang L, Zhang J, Stockard CR, Grizzle WE, Fallon MB: Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. Journal of hepatology 2003,38:556-563.

[26] Ling Y, Zhang J, Luo B, Song D, Liu L, Tang L, Stockard CR, Grizzle WE, Ku DD, Fallon MB: The role of endothelin-1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat.Hepatology 2004, 39:1593-1602.

[27] Luo B, Tang L, Wang Z, Zhang J, Ling Y, Feng W, Sun JZ, Stockard CR, Frost AR, Chen YF, Grizzle WE,Fallon MB: Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterology 2005, 129:682-695.

[28] Liu M, Tian D, Wang T, Tang W, Liang K: Correlation between pulmonary endothelin receptors and alveolar-arterial oxygen gradient in rats with hepatopulmonary syndrome. Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban =Huazhong keji daxue xuebao Yixue Yingdewen ban 2005, 25:494-496.

[29] Liu L, Liu N, Zhao Z, Liu J, Feng Y, Jiang H, Han D: TNF-αlpha neutralization improves experimental hepatopulmonary syndrome in rats. Liver international: offcial journal of the International Association for the Study of the Liver 2012, 32:1018-1026.

[30] Zhang J, Ling Y, Tang L, Luo B, Pollock DM, Fallon MB: Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-defcient rats. American journal of physiology Gastrointestinal and liver physiology 2009, 296:G704-G708.

[31] Arguedas MR, Drake BB, Kapoor A, Fallon MB: Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology 2005, 128:328-333.

[32] Shi-bin GUO, Zhi-jun D, Qing LI, Xiao-yu SUN, After S, However S: Effects of heme oxygenase-1 on pulmonary function and structure in rats with liver cirrhosis. Chinese Medical Journal 2011, 124:918-922.

[33] Aller R, de Luis DA, Moreira V, Boixeda D, Moya JL, Fernandez-Rodriguez CM, San Roman AL, Avila S, Barcena R: The effect of liver transplantation on circulating levels of estradiol and progesterone in male patients: parallelism with hepatopulmonary syndrome and systemic hyperdynamic circulation improvement.Journal of endocrinological investigation 2001, 24:503-509.

[34] Yol S, Erikoglu M, Toprak SS, Tavli S, Tavli L: The effects of serum estrogen levels on hypoxemia and blood nitric oxide levels in experimental hepatopulmonary syndrome. Hepatology research: the official journal of the Japan Society of Hepatology 2005, 33:7-13.

[35] Katsuta Y: Estrogen promotes intrapulmonary vasodilatation in hepatopulmonary syndrome. Hepatology research: the offcial journal of the Japan Society of Hepatology 2005, 33:1-4.

[36] Oswald-Mammosser M, Rashid S, Boehm N, Agin A, Geny B, Kerth VS, Charloux A: Effect of the estrogen receptor antagonist fulvestrant on the cirrhotic rat lung. Fundamental & clinical pharmacology 2015.

[37] Zhang HY, Han de W, Su AR, Zhang LT, Zhao ZF, Ji JQ, Li BH, Ji C: Intestinal endotoxemia plays a central role in development of hepatopulmonary syndrome in a cirrhotic rat model induced by multiple pathogenic factors. World journal of gastroenterology: WJG 2007, 13:6385-6395.

[38] Zhang HY, Han DW, Zhao ZF, Liu MS, Wu YJ, Chen XM, Ji C: Multiple pathogenic factor-induced complications of cirrhosis in rats: a new model of hepatopulmonary syndrome with intestinal endotoxemia.World journal of gastroenterology: WJG 2007, 13:3500-3507.

[39] Wang WB, Jia CK, Liang L: [Reduction of endotoxin may protect lung from injury in rats with hepatopulmonary syndrome]. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences 2007, 36:285-290.

[40] Zhang HY, Han DW, Wang XG, Zhao YC, Zhou X, Zhao HZ: Experimental study on the role of endotoxin in the development of hepatopulmonary syndrome. World journal of gastroenterology: WJG 2005, 11:567-572.

[41] Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM: Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clinical gastroenterology and hepatology:the offcial clinical practice journal of the American Gastroenterological Association 2010, 8:1095-1098.

[42] Gaio E, Amado V, Rangel L, Huang W, Storck R, Melo-Silva CA: Levofloxacin decreased chest wall mechanical inhomogeneities and airway and vascular remodeling in rats with induced hepatopulmonary syndrome. Respiratory physiology & neurobiology 2013, 189:565-570.

[43] Assimakopoulos SF, Gogos C, Labropoulou-Karatza C: Could antioxidants be the “magic pill” for cirrhosisrelated complications? A pathophysiological appraisal. Medical hypotheses 2011, 77:419-423.

[44] Zhang J, Yang W, Luo B, Hu B, Maheshwari A, Fallon MB: The role of CX(3)CL1/CX(3)CR1 in pulmonary angiogenesis and intravascular monocyte accumulation in rat experimental hepatopulmonary syndrome.Journal of hepatology 2012, 57:752-758.

[45] Zhang J, Luo B, Tang L, Wang Y, Stockard CR, Kadish I, Van Groen T, Grizzle WE, Ponnazhagan S,Fallon MB: Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology 2009,136:1070-1080.

[46] Thenappan T, Goel A, Marsboom G, Fang YH, Toth PT, Zhang HJ, Kajimoto H, Hong Z, Paul J, Wietholt C, Pogoriler J, Piao L, Rehman J, Archer SL: A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. American journal of respiratory and critical care medicine 2011, 183:1080-1091.

[47] Zhang J, Yang W, Hu B, Wu W, Fallon MB: Endothelin-1 activation of the endothelin B receptor modulates pulmonary endothelial CX3CL1 and contributes to pulmonary angiogenesis in experimental hepatopulmonary syndrome. The American journal of pathology 2014, 184:1706-1714.

[48] Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Le Pape A, de Montpreville V, Mazmanian M,Humbert M, Herve P: Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. The European respiratory journal 2004, 23:752-758.

[49] Aljudaibi B, Qumosani K, Chandok N: Pentoxifylline for slow to resolve hepatopulmonary syndrome post liver transplantation: helpful or unnecessary? Acta gastro-enterologica Belgica 2013, 76:70-1.

[50] Kim MY, Baik SK, Lee SS: Hemodynamic alterations in cirrhosis and portal hypertension. The Korean journal of hepatology 2010, 16:347-352.

[51] Dimmeler S, Zeiher A: Akt Takes Center Stage in Angiogenesis Signaling. Circulation Research 2000, 86:4-6.

[52] Articles A: The Role of Vascular Endothelial Growth Factor in Pulmonary Arterial Hypertension: The angiogenesis paradox. American Journal of Respiratory cell and molecular biology 2014.

[53] Breen EC: VEGF in biological control. Journal of cellular biochemistry 2007, 102:1358-1367.

[54] Yang W, Zhang J, Hu B, Wu W, Venter J, Alpini G, Fallon MB: The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome. American journal of physiology Gastrointestinal and liver physiology 2014, 306:G72-G80.

[55] Chang CC, Chuang CL, Lee FY, Wang SS, Lin HC, Huang HC, Teng TH, Hsu SJ, Hsieh HG, Lee SD:Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. Clinical science 2013, 124:457-466.

[56] Zeng J, Yi B, Wang Z, Ning J, Wang X, Lu K: Effect of annexin A2 on hepatopulmonary syndrome rat serum-induced proliferation of pulmonary arterial smooth muscle cells. Respiratory physiology &neurobiology 2013, 185:332-338.

[57] Chen L, Li YS, Cui J, Ning JN, Wang GS, Qian GS, Lu KZ, Yi B: MiR-206 controls the phenotypic modulation of pulmonary arterial smooth muscle cells induced by serum from rats with hepatopulmonary syndrome by regulating the target gene, annexin A2. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 2014, 34:1768-1779.

[58] Zhang H, Lv M, Zhao Z, Jia J, Zhang L, Xiao P, Wang L, Li C, Ji J, Tian X, Li X, Fan Y, Lai L, Liu Y, Li B,Zhang C, Liu M, Guo J, Han D, Ji C: Glucose-regulated protein 78 may play a crucial role in promoting the pulmonary microvascular remodeling in a rat model of hepatopulmonary syndrome. Gene 2014, 545:156-162.

[59] Chen B, Ning JL, Gu JT, Cui J, Yang Y, Wang Z, Zeng J, Yi B, Lu KZ: Caspase-3 inhibition prevents the development of hepatopulmonary syndrome in common bile duct ligation rats by alleviating pulmonary injury. Liver international: offcial journal of the International Association for the Study of the Liver 2015,35:1373-1382.

[60] Tumgor G, Berdeli A, Arikan C, Levent E, Aydogdu S: Mcp-1, eNOS, tPA and PAI-1 gene polymorphism and correlation of genotypes and phenotypes in hepatopulmonary syndrome. Digestive diseases and sciences 2008, 53:1345-1351.

[61] Roberts KE, Kawut SM, Krowka MJ, Brown RS, Jr., Trotter JF, Shah V, Peter I, Tighiouart H, Mitra N,Handorf E, Knowles JA, Zacks S, Fallon MB, Pulmonary Vascular Complications of Liver Disease Study G:Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology 2010, 139:130-9 e24.

[62] Postles A, Clark A, Tawhai M: Dynamic Blood Flow and Wall Shear Stress in Pulmonary Hypertensive Disease. Engineering in Medicine and Biology Society 2014.

[63] Yamamoto K, Ando J: New molecular mechanisms for cardiovascular disease:blood fow sensing mechanism in vascular endothelial cells. Journal of pharmacological sciences 2011, 116:323-331.

[64] De Laet IE, Ravyts M, Vidts W, Valk J, De Waele JJ, Malbrain ML: Current insights in intra-abdominal hypertension and abdominal compartment syndrome: open the abdomen and keep it open! Langenbecks Arch Surg 2008, 393:833-847.

[65] Doty JM, Oda J, Ivatury RR, Blocher CR, Christie GE, Yelon JA, Sugerman HJ: The effects of hemodynamic shock and increased intra-abdominal pressure on bacterial translocation. J Trauma 2002, 52:13-17.

[66] Kesici U, Kesici S, Polat E, Agca B, Turkmen UA, Ozcan D, Sari MK: Effects of intra-abdominal pressure increase on intestinal ischemia and bacterial translocation in experimental sepsis model. Saudi Med J 2011,32:813-817.

[67] Zhang Z, Qi X, Li Z, Xu L, Wang F, Wang S, Chang Y, Ma W, Xu M, Yang C: Hepatopulmonary syndrome:the role of intra-abdominal hypertension and a novel mouse model. International journal of clinical and experimental pathology 2014, 7:768-773.

[68] Nacif LS, Andraus W, Kubrusly MS, Kubrusly FS, Gebara VC, Ishizawa A, D'Albuquerque LA: Surfactant protein A is decreased in the lung of rats with hepatopulmonary syndrome. Acta cirurgica brasileira /Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia 2014, 29:573-578.

[69] Yang W, Hu B, Wu W, Batra S, Blackburn MR, Alcorn JL, Fallon MB, Zhang J: Alveolar type Ⅱ epithelial cell dysfunction in rat experimental hepatopulmonary syndrome (HPS). PloS one 2014, 9:e113451.